

Non Clinical Trials Market - 2022-2030

<https://marketpublishers.com/r/N3B15BB492CBEN.html>

Date: November 2025

Pages: 218

Price: US\$ 2,999.00 (Single User License)

ID: N3B15BB492CBEN

Abstracts

The Non Clinical Trials Market was valued at US\$ 11.5 billion in 2022 and is anticipated to reach US\$ 15.3 billion by 2030, at a CAGR of 0.045 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Non Clinical Trials Market.

This report delivers a comprehensive overview of the Non Clinical Trials Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non Clinical Trials Market. The Non Clinical Trials Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–2030.

Non Clinical Trials Market Scope:

By Study Type

Pharmacodynamics (PD) studies

Pharmacokinetics (PK) studies

Toxicology studies

By Test

In silico

In vitro

In vivo

By Therapeutic Area

Oncology

Cardiovascular

Neurology

Immunology

Others

By End User

Pharmaceutical and Biotechnology Companies

Contract Research Organizations (CROs)

Academic and Government Research Institutes

Others

Key Players

Labcorp Drug Development

Charles River Laboratories

PPD (Pharmaceutical Product Development)

ICON plc

Novartis AG

Merck & Co., Inc.

AstraZeneca plc

CMIC HOLDINGS Co., LTD

ProPharma

MorphoSys AG

Major Highlights

This report delivers a comprehensive overview of the Non Clinical Trials Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non Clinical Trials Market. The Non Clinical Trials Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–2030.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest

of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the

privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Study Type
- 3.2. Snippet by Test
- 3.3. Snippet by Therapeutic Area
- 3.4. Snippet by End User
- 3.5. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. The rising prevalence of Group B Streptococcus
 - 4.1.1.2. The rising the clinical trials on Group B Streptococcus
 - 4.1.2. Restraints
 - 4.1.2.1. Extensive testing and documentation can often result in delays
 - 4.1.3. Opportunity
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Russia-Ukraine War Impact Analysis
- 5.6. DMI Opinion

6. COVID-19 ANALYSIS

- 6.1. Analysis of COVID-19
 - 6.1.1. Scenario Before COVID
 - 6.1.2. Scenario During COVID
 - 6.1.3. Scenario Post COVID
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion

7. BY STUDY TYPE

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
 - 7.1.2. Market Attractiveness Index, By Study Type
- 7.2. Pharmacodynamics (PD) studies *
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Pharmacokinetics (PK) studies
- 7.4. Toxicology studies

8. BY TEST

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
 - 8.1.2. Market Attractiveness Index, By Test
- 8.2. In silico *
 - 8.2.1. Introduction
 - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. In vitro
- 8.4. In vivo

9. BY THERAPEUTIC AREA

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
 - 9.1.2. Market Attractiveness Index, By Therapeutic Area
- 9.2. Oncology *
 - 9.2.1. Introduction

- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Cardiovascular
- 9.4. Neurology
- 9.5. Immunology
- 9.6. Others

10. BY END USER

- 10.1. Introduction
 - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
 - 10.1.2. Market Attractiveness Index, By End User
- 10.2. Pharmaceutical and Biotechnology Companies s*
 - 10.2.1. Introduction
 - 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Contract Research Organizations (CROs)
- 10.4. Academic and Government Research Institutes
- 10.5. Others

11. BY REGION

- 11.1. Introduction
 - 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 11.1.2. Market Attractiveness Index, By Region
- 11.2. North America
 - 11.2.1. Introduction
 - 11.2.2. Key Region-Specific Dynamics
 - 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
 - 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
 - 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
 - 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
 - 11.2.6.1. U.S.
 - 11.2.6.2. Canada
 - 11.2.6.3. Mexico
- 11.3. Europe
 - 11.3.1. Introduction
 - 11.3.2. Key Region-Specific Dynamics
 - 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
 - 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
 - 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test

- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 11.3.8.1. Germany
 - 11.3.8.2. UK
 - 11.3.8.3. France
 - 11.3.8.4. Italy
 - 11.3.8.5. Spain
 - 11.3.8.6. Rest of Europe
- 11.4. South America
 - 11.4.1. Introduction
 - 11.4.2. Key Region-Specific Dynamics
 - 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
 - 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
 - 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
 - 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
 - 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 11.4.7.1. Brazil
 - 11.4.7.2. Argentina
 - 11.4.7.3. Rest of South America
- 11.5. Asia-Pacific
 - 11.5.1. Introduction
 - 11.5.2. Key Region-Specific Dynamics
 - 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
 - 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
 - 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
 - 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
 - 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 11.5.7.1. China
 - 11.5.7.2. India
 - 11.5.7.3. Japan
 - 11.5.7.4. Australia
 - 11.5.7.5. Rest of Asia-Pacific
- 11.6. Middle East and Africa
 - 11.6.1. Introduction
 - 11.6.2. Key Region-Specific Dynamics
 - 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Type
 - 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
 - 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area

11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. COMPETITIVE LANDSCAPE

- 12.1. Competitive Scenario
- 12.2. Market Positioning/Share Analysis
- 12.3. Mergers and Acquisitions Analysis

13. COMPANY PROFILES

- 13.1. Labcorp Drug Development *
 - 13.1.1. Company Overview
 - 13.1.2. Product Portfolio and Description
 - 13.1.3. Financial Overview
 - 13.1.4. Key Developments
- 13.2. Charles River Laboratories
- 13.3. PPD (Pharmaceutical Product Development)
- 13.4. ICON plc
- 13.5. Novartis AG
- 13.6. Merck & Co., Inc.
- 13.7. AstraZeneca plc
- 13.8. CMIC HOLDINGS Co., LTD
- 13.9. ProPharma
- 13.10. MorphoSys AG (*LIST NOT EXHAUSTIVE)

14. APPENDIX

- 14.1. About Us and Services
- 14.2. Contact Us

I would like to order

Product name: Non Clinical Trials Market - 2022-2030

Product link: <https://marketpublishers.com/r/N3B15BB492CBEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N3B15BB492CBEN.html>